20 Takeover Rumors Hedge Funds Are Buying

13. ADMA Biologics, Inc. (NASDAQ:ADMA)

No. of Hedge Funds: 37

Headquartered in New Jersey, a biopharmaceutical company, ADMA Biologics, Inc. (NASDAQ:ADMA) specializes in developing and commercializing plasma-derived biologics. These are used to treat and prevent infectious diseases in immunocompromised patients. The company’s flagship products include ASCENIV and BIVIGAM. It emphasizes FDA-approved production capabilities and expansion of its plasma collection network to compete with other players. With clinical efficiency, the company addresses critical gaps in immune globulin therapy.

After acquiring a high level of the company’s stake (5.6%) by activist investors Caligan Partners in February 2022, ADMA Biologics, Inc. (NASDAQ:ADMA) has been the subject of takeover rumors. Caligan Partners, after acquiring the stake, has reportedly urged the company to consider a potential sale through a strategic review. Accordingly, in the recent quarters, many concerns have been raised with respect to the company’s financial reporting, including the resignation of its independent outside auditor, CohnReznick LLP. However, the matter was subsequently settled with Kirby McInerney LLP. Significant shareholder activities and the recently emerging concerns could lead to potential takeovers by pharmaceutical or biotech companies.

We noted a total of 37 hedge funds taking positions in ADMA Biologics, Inc. (NASDAQ:ADMA), as per Insider Monkey’s Q4 2024 database. It points to a fair degree of institutional confidence, likely partly driven by the circulating takeover rumors.